These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30203839)

  • 1. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
    van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
    Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Idiopathic Castleman Disease.
    van Rhee F; Greenway A; Stone K
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
    Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
    Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
    Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
    Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
    Pierson SK; Katz L; Williams R; Mumau M; Gonzalez M; Guzman S; Rubenstein A; Oromendia AB; Beineke P; Fosså A; van Rhee F; Fajgenbaum DC
    Nat Commun; 2022 Nov; 13(1):7236. PubMed ID: 36433996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Kurzrock R
    Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
    Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
    Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
    Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R; Ferrero S; Sato Y; Schey S; Dispenzieri A; Oksenhendler E; Zinzani PL; Lechowicz MJ; Hoffmann C; Pemmaraju N; Bagg A; Fossa A; Lim MS; van Rhee F;
    Am J Hematol; 2020 Dec; 95(12):1553-1561. PubMed ID: 32894785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.